DMS triggers apoptosis associated with the inhibition of SPHK1/NF-κB activation and increase in intracellular Ca2+ concentration in human cancer cells

International Journal of Molecular Medicine

Volumn 33, Issue 1, 2014, Pages 17-24

  Chen, Kan ^a,b   Pan, Qiuwei ^b   Gao, Ying ^c   Yang, Xinyan ^a   Wang, Shibing ^a   Peppelenbosch, Maikel P ^b   Kong, Xiangdong ^a  

^a ZHEJIANG SCI TECH UNIVERSITY   (China)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Intracellular calcium concentration; N,N dimethyl D erythro sphingosine; Nuclear factor B pathway; Sphingosine kinase 1

Indexed keywords

CALCIUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N,N DIIMETHYL DEXTRO ERYTHRO SPHINGOSINE; SPHINGOSINE; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CANCER CELL CULTURE; CELL CULTURE; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CALCIUM; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DNA FRAGMENTATION; HUMANS; LUNG NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84892759547     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1541     Document Type: Article

References (41)

1. Igarashi Y and Hakomori S: Enzymatic synthesis of N, N-dimethyl- sphingosine: demonstration of the sphingosine: N-methyltransferase in mouse brain. Biochem Biophys Res Commun 164: 1411-1416, 1989.
2. Megidish T, Cooper J, Zhang L, Fu H and Hakomori S: A novel sphingosine-dependent protein kinase (SDK1) specifically phosphorylates certain isoforms of 14-3-3 protein. J Biol Chem 273: 21834-21845, 1998.
3. 2+ signalling by G-protein-coupled receptors. EMBO J 17: 2830-2837, 1998.
4. Edsall LC, Van Brocklyn JR, Cuvillier O, Kleuser B and Spiegel S: N,N-dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry 37: 12892-12898, 1998.
5. Sakakura C, Sweeney EA, Shirahama T, et al: Selectivity of sphingosine-induced apoptosis. Lack of activity of DL-erythyro- dihydrosphingosine. Biochem Biophys Res Commun 246: 827-830, 1998.
6. Cuvillier O, Pirianov G, Kleuser B, et al: Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381: 800-803, 1996.
7. Antoon JW, White MD, Slaughter EM, et al: Targeting NFκB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 11: 678-689, 2011.
8. Billich A, Bornancin F, Mechtcheriakova D, Natt F, Huesken D and Baumruker T: Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: function in cell survival and IL-1beta and TNF-alpha induced production of inflammatory mediators. Cell Signal 17: 1203-1217, 2005.
9. Alfonso A, De la Rosa L, Vieytes M and Botana L: Dimethylsphingosine increases cytosolic calcium and intracellular pH in human T lymphocytes. Biochem Pharmacol 65: 465-478, 2003.
10. Lee EH, Lee YK, Im YJ, Kim JH, Okajima F and Im DS: Dimethylsphingosine regulates intracellular pH and Ca(2+) in human monocytes. J Pharmacol Sci 100: 289-296, 2006.
11. Shin Y, Daly J and Choi O: Diverse effects of sphingosine on calcium mobilization and influx in differentiated HL-60 cells. Cell Calcium 27: 269-280, 2000.
12. 2+ in the U937 monocyte cell line. Arch Pharm Res 29: 657-665, 2006.
13. 2+-exchanger in HCT116 human colon cancer cells. Arch Pharm Res 31: 54-59, 2008.
14. Pchejetski D, Golzio M, Bonhoure E, et al: Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 65: 11667-11675, 2005.
15. Morales A, Paris R, Villanueva A, Llacuna L, Garcia-Ruiz C and Fernandez-Checa J: Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Oncogene 26: 905-916, 2007.
16. Bonhoure E, Pchejetski D, Aouali N, et al : Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting shingosine kinase-1. Leukemia 20: 95-102, 2006.
17. Vadas M, Xia P, McCaughan G and Gamble J: The role of sphingosine kinase 1 in cancer: Oncogene or non-oncogene addiction? Biochimica et Biophysica Acta (BBA). Biochim Biophys Acta 1781: 442-447, 2008.
18. Nava VE, Cuvillier O, Edsall LC, et al: Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res 60: 4468-4474, 2000.
19. Nava VE, Hobson JP, Murthy S, Milstien S and Spiegel S: Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res 281: 115-127, 2002.
20. Sweeney EA, Sakakura C, Shirahama T, et al: Sphingosine and its methylated derivative N,N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int J Cancer 66: 358-366, 1996.
21. Liu H, Sugiura M, Nava VE, et al: Molecular cloning and func tional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 275: 19513-19520, 2000.
22. Olivera A, Kohama T, Tu Z, Milstien S and Spiegel S: Purification and characterization of rat kidney sphingosine kinase. J Biol Chem 273: 12576-12583, 1998.
23. Ruckhäberle E, Rody A, Engels K, et al: Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 112: 41-52, 2008.
24. French KJ, Schrecengost RS, Lee BD, et al: Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63: 5962-5969, 2003.
25. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK and Smith CD: Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 318: 596-603, 2006.
26. Akao Y, Banno Y, Nakagawa Y, et al: High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem Biophys Res Commun 342: 1284-1290, 2006.
27. Leroux M, Auzenne E, Evans R, et al: Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells. Prostate 67: 1699-1717, 2007.
28. Sutphen R, Xu Y, Wilbanks GD, et al: Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13: 1185-1191, 2004.
29. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ and Prior TW: Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 64: 695-705, 2005.
30. Suzuki H, Riley RT and Sharma RP: Inducible nitric oxide has protective effect on fumonisin B1 hepatotoxicity in mice via modulation of sphingosine kinase. Toxicology 229: 42-53, 2007.
31. Kawamori T, Osta W, Johnson KR, et al: Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 20: 386-388, 2006.
32. Sobue S, Nemoto S, Murakami M, et al: Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells. Int J Hematol 87: 266-275, 2008.
33. Johnson KR, Johnson KY, Crellin HG, et al : Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem 53: 1159-1166, 2005.
34. Min J, Van Veldhoven PP, Zhang L, Hanigan MH, Alexander H and Alexander S: Sphingosine-1-phosphate lyase regulates sensitivity of human cells to select chemotherapy drugs in a p38-dependent manner. Mol Cancer Res 3: 287-296, 2005.
35. Sauer B, Ruwisch L and Kleuser B: Antiapoptotic action of 1alpha,25-dihydroxyvitamin D3 in primary human melanocytes. Melanoma Res 13: 339-347, 2003.
36. Bektas M, Jolly PS, Müller C, Eberle J, Spiegel S and Geilen CC: Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 24: 178-187, 2005.
37. Han S and Roman J: Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun 314: 1093-1099, 2004.
38. Mukogawa T, Koyama F, Tachibana M, et al: Adenovirus-mediated gene transduction of truncated I kappa B alpha enhances radiosensitivity in human colon cancer cells. Cancer Sci 94: 745-750, 2003.
39. Weaver KD, Yeyeodu S, Cusack JC Jr, Baldwin AS Jr and Ewend MG: Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61: 187-196, 2003.
40. Lin JC, Yang SC, Hong TM, et al: Phenanthrene-based tylophorine-1 (PBT-1) inhibits lung cancer cell growth through the Akt and NF-kappaB pathways. J Med Chem 52: 1903-1911, 2009.
41. Gong G, Waris G, Tanveer R and Siddiqui A: Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 98: 9599-9604, 2001.